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Arachidonic acid is metabolized by cyclooxygenases (COX-1 and COX-2) into various 
prostanoids which exert different functions in mammalian physiology. One of these prostanoids, 
prostaglandin E2 (PGE2), interacts with four different G protein-coupled receptors, named EP1, 
EP2, EP3 and EP4, to initiate different downstream signaling pathways. Prostanoid receptors are 
diversely expressed throughout different tissues all over the body and PGE2 is responsible for a 
large variety of beneficial and disadvantageous effects. We have recently achieved a greater 
understanding of the biology of prostanoid E receptors and the potential for specific drug 
targeting with the advent of potent and selective EP receptor agonists and antagonists. This has 
important implications for lung health and disease as PGE2-mediated EP receptor activation 
impacts upon migration of airway smooth muscle cells, airway microvascular leak, tone 
regulation of pulmonary blood vessels, mast cell  degranulation, bronchodilatation, cough, 
angiogenesis and airway inflammation, to name a few.  
In this review, we overview the EP receptor family and the related signalling pathways, 
summarize a variety of EP1-4 receptor agonists and antagonists, provide an overview of 
pharmacological tools used to implicate EP receptor function in the context of respiratory health 
and disease and finally highlight some of the more selective pharmacological reagents that have 
recently been developed. The availability of selective pharmacological agonists and antagonists 
for the distinct EP receptors, as well as the development of specific prostanoid receptor knock-
out mice, offer hitherto unattainable opportunities for achieving an in depth understanding of the  
role and function of PGE2 in respiratory disease and the exciting potential of targeting EP 
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Prostaglandin E2 (PGE2) is an important lipid mediator that activates four different prostanoid E 
(EP) receptors, termed EP1, EP2, EP3, and EP4. Along with other important prostanoids, 
including PGD2, PGF2α, prostacyclin (PGI2), and thromboxane A2 (TxA2), PGE2 is synthesized 
from arachidonic acid by cyclooxygenase (COX) enzymes via the unstable intermediate forms 
PGG2 and PGH2 [1, 2]. EP1-4 are G protein-coupled receptors (GPCR) that form part of 
prostanoid receptor family that include receptors for other endogenous prostanoid ligands, 
including DP1-2 (for PGD2), FP (for PGF2α), IP (for PGI2) and TP (for TxA2). 
PGE2 exhibits various functions in the human body which can be either beneficial or 
disadvantageous. With the relatively recent development of selective EP receptor antagonists and 
agonists it will be possible to examine ligand-mediated cell signalling pathways triggered via the 
EP receptors, well as the effects of the individual EP receptors more closely. This is especially 
important in the respiratory setting, where targeting the EP receptor system offers great potential 
as novel therapeutics to combat chronic respiratory diseases and lung conditions [3]. To date 
however, the EP receptor antagonists and agonists available have shown varying degrees of 
potency and selectively. Some of these have been used in the respiratory setting and offer a 
convenient pharmacological means to target EP receptors and demonstrate functional outcomes. 
However, these compounds do not always target the receptors they say they target. Often 
receptor identification has been incorrectly assigned based on the promiscuous nature of the 
agonist/antagonist.  
Given that prostanoids are currently enjoying a renaissance, and that ligand-mediated cell 
signalling pathways triggered via EP receptors have broad implications in health and disease, it 
is important to have an understanding of the EP receptor family and to utilize selective 
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pharmacological agents. We address this herein and review the EP receptor family and the 
signalling pathways that are activated upon ligand binding (PGE2 in particular). We will then 
provide a summary of some of the EP1-4 receptor agonists and antagonists and offer an 
assessment of their selectivity. We will then focus on the respiratory setting and provide an 
overview of the agonists/antagonists used to implicate EP receptor function in the context of 
respiratory health and disease. Finally, we will highlight some of the more selective 
pharmacological reagents that recently been developed and underscore the promise of utilizing 
transgenic mice where a particular EP receptor has been knocked-out. These murine models are 
able to distinctly implicate a particular EP receptor in a precise manner. When coupled with 
validated experimental models of respiratory disease, these tools will allow researchers to more 
clearly define molecular mechanisms responsible for disease pathogenesis and enable improved 
treatments in the future. 
I. Ligand-mediated cellular signalling via EP receptors 
A. EP1 receptor 
1. Receptor 
EP1 was the first characterized EP receptor. Compared to other EP receptor subtypes, EP1 is not 
widely distributed and its expression in animal tissue is relatively low, mostly occurring in 
kidney and lung tissue [1]. The human EP1-receptor consists of 402 amino acids. In terms of 
amino acid sequence identity, the human EP1 receptor is more closely related to the TXA2 
receptor, followed by EP3, EP2 and EP4 [4]. The human EP1 receptor is 86% homologous with 
the rat EP1-receptor (rEP1). In rats, Okuda-Ashitaka et al. [5] identified a variant: when the 
mRNAs of rEP1 and of the rEP1-variant were compared it became clear that the mRNA of the 
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rEP1-variant is the unspliced form of the rEP1-mRNA [5]. The mouse and rat EP1 receptors share 
a sequence homology of 96% [5]. 
2. Signalling 
One of the major signalling outcomes from engagement of PGE2 with the EP1 receptor is 
increased levels of intracellular Ca2+ [6]. When both receptors, rEP1 and its variant, were 
expressed in Chinese hamster ovary (CHO) cells and the rEP1-receptor activated, Ca
2+ 
mobilization was significantly subdued. Co-expression of EP4 and the rEP1-variant in CHO cells 
led to a blockade of cAMP formation after activation of EP4 [5]. These findings suggest that the 
rat EP1 receptor variant is able to suppress the signalling of other receptors for PGE2. 
Although it is generally well accepted that EP1 stimulation generates intracellular Ca
2+ increase 
resulting in smooth muscle contraction, there are differing opinions about the coupling of the 
receptor, the activation of phospholipase C (PLC) and the hydrolysis of phosphatidylinositol [7]. 
Coleman et al. [1] stated that Ca2+ mobilization from intracellular stores is mediated via an 
inositol triphosphate (IP3)-independent mechanism via EP1. This was due to the fact that PGE2-
induced Ca2+ mobilization is not blocked by pertussis toxin and does not require extracellular 
Ca2+ [1]. Moreover, changes in cAMP were negligible in CHO-cells expressing recombinant 
murine EP1 receptors. In contrast, Watabe et al. [8] showed that the increase of intracellular Ca
2+ 
by engagement of the EP1 receptor was completely abolished by removal of extracellular Ca
2+; 
therefore suggesting that the PGE2- induced increase in Ca
2+ is due to the entry of extracellular 
Ca2+ [8]. Additionally, Katoh et al. observed two different ways of increasing intracellular Ca2+. 
Stimulation of mouse EP1- receptor in cDNA-transfected CHO cells leads to an entry of 
extracellular Ca2+ inside the cell which again results in hydrolysis of phosphatidylinositol. This 
process is independent of PLC. There is also Ca2+- mobilization from internal stores, but in 
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contrast to extracellular Ca2+- influx, it is relatively weakly induced [9]. This process is sensitive 
to PLC inhibitors [10]. Protein kinase C affects the regulation of EP1 signal transduction as it 
induces short- and long-term desensitization of this receptor. Further research is required to 
reconcile these cellular signalling differences. 
There is also evidence that the EP1 receptor also couples to Gq/11 and Gi/o. Tests with antisense 
oligodeoxynucleotides in the Xenopus oocyte expression system performed by Tabata et al. 
demonstrated that EP1 receptors can induce Ca
2+ mobilization via Gq/11 [10]. Ji et al. [7] showed 
that PGE2 clearly stimulated intracellular IP3 accumulation in HEK293 cells expressing the 
human EP1 receptor via coupling to Gq/11. They also reported that the EP1 receptor could couple 
to Gi/o to activate multiple signalling pathways (ribosomal S6 kinases, phosphatidylinositol-3-
kinase (PI3K), Akt and mammalian target of rapamycin) in a pertussin toxin-sensitive manner 
[7].  
Moreover, it has been demonstrated that the interaction time between PGE2 and the EP1 receptor, 
compared to some of the other EP receptors, is relatively rapid. Association and dissociation of 
the ligand PGE2 takes 30 seconds on EP1, whereas association with and dissociation from EP2 
takes 10 and 5 minutes [9]. In EP3 receptors these processes requires 10 minutes and 80 minutes, 
respectively [9].  
B. EP2 and EP4 receptors 
1. Receptors 
EP2 and EP4 receptors will be discussed together in this section due to their similarities. Until 
1995 the EP4 receptor was unknown and only three forms of EP receptors had been described in 
the literature. The discovery of the EP4 receptor was driven by a mistake, as the receptor first 
thought to be the EP2 receptor was in fact the EP4 receptor [11]. The true identity was soon to be 
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published and further investigations of this new receptor were performed [12-14]. EP2 and EP4 
receptors differ in the length of the C-terminal sequence, as the EP2 receptor has a rather short C-
terminal sequence while the EP4 receptor has a long C-terminal sequence [2]. EP2 and EP4 
receptors show similar binding profiles and both mediate cellular signalling via adenylate cyclase 
activity resulting in increased levels of intracellular cAMP [15]. Although they demonstrate 
similarities in pharmacology and functional coupling, EP2 and EP4 receptors do not share high 
levels of amino acid identity: only ~38% homology in the transmembrane domain [16]. 
Phylogenetic analysis shows that the EP2 receptor is more closely related to other relaxant 
prostanoid receptors, such as the IP and DP receptors [17], than the other EP receptors. Overall, 
there exists about ~30% identity with the other receptors, i.e. ~37% with EP1 and ~ 34% with 
EP3 [12, 16]. 
2. Signalling 
Engagement of EP2 and EP4 receptors activate adenylate cyclase activity [1] resulting in cAMP 
increase [15]. When cAMP activates protein kinase A (PKA), the release of the PKA catalytic 
subunits allows them to phosphorylate a wide range of cellular targets, resulting in myriad 
cellular effects [1, 18]. Adenylate cyclase/cAMP/PKA signalling after PGE2 stimulation of EP2 
and EP4 receptors occurs in a Gs-coupled manner and can induce phosphorylation of the 
transcription factor, cAMP response element binding protein (CREB) at serine-133 resulting. 
This results in transcriptional regulation of genes containing promoters containing CRE 
consensus sequences. As EP2 and EP4 receptors are widely distributed throughout the body [19], 
receptor response to mediators is widespread: for example, relaxation in smooth muscle cells, 
non-acid secretion on epithelial cells and inhibition of mediator release in inflammatory cells, to 
name a few [1, 18].   
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But EP2 and EP4 receptors do show differences in their regulation following treatment with 
PGE2. While the EP4 receptor undergoes short term agonist-induced desensitization and 
internalization, the EP2 receptor does not; although receptors show downregulation upon long-
term exposure (>2 hour) to an agonist [20, 21]. Additionally, there are differences in the amount 
of cAMP produced upon stimulation. When receptors are stably expressed in HEK293 cells (at 
similar levels of receptor expression), the maximal amount of cAMP formation by stimulated 
EP4 receptors is only 20 to 50% of that achieved amount by EP2 stimulation  [22, 23].  
In addition to the well-recognized role played by adenylate cyclase in mediating the EP2 and 
EP4-mediated cellular signalling responses to ligands, other pathways have been reported. A 
notable example is the activation of T-cell factor (TCF) signalling via glucogen synthase kinase-
3 (GSK-3), the enzyme responsible for phosphorylating and thus destabilizing β-catenin. GSK-3 
can be inactivated by phosphorylation, this process can be induced by EP2 and EP4-mediated 
cellular signalling [22, 24, 25]. The common canonical signalling pathway starts with the Wnt 
ligand binding to the Frizzled receptor. Dishevelled is then recruited and results in the inhibition 
of the kinase activity of GSK-3. Active GSK-3 promotes the instability of β-catenin via 
phosphorylation and thus addition of ubiquitin, leading to degradation by the proteasome. When 
stable, β-catenin can interact with TCF DNA-binding factors to form a transcriptionally active 
complex that can alter gene expression. The involvement of EP2 and EP4 in this pathway was 
implicated by Fujino et al. [22] through utilization of TCF-responsive luciferase reporter genes 
in HEK293 cells transfected with human EP2 and EP4 receptors. They showed that activation of 
these receptors with the ligand PGE2 can activate TCF signalling. Furthermore, stimulation of 
reporter genes with PGE2 was aligned with phosphorylation of GSK-3, PI3K/Akt and activation 
of TCF signalling. Moreover, EP2 receptor signalling occurred primarily through a PKA-
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dependent pathway, while EP4 receptors activate TCF signalling primarily by a PI3K-dependent 
pathway [22]. 
Additional studies provide further evidence linking stimulation of EP4 receptors with the PI3K 
pathway. PGE2 treatment leads to PI3K-dependant phosphorylation of extracellular signal-
regulated kinase (ERK). This PI3K-dependent pathway can only be induced by EP4 receptors, 
not EP2 receptors [26]. As EP2 and EP4 receptors differ in their agonist-induced internalization 
and desensitization and since internalization of GPCRs has been described to be associated with 
a transactivation of the mitogen-activated protein kinase (MAPK) pathway there may be a link 
between the activation of ERK and the selective internalization [26-28].  
As outlined earlier, phosphorylation of CREB was originally be shown to occur via the classical 
cAMP-dependent PKA pathway, but further experiments with pharmacological inhibitors 
proposed that PKA is not the only kinase with the ability of phosphorylating CREB after 
EP2/EP4 ligation. Phosphorylation of CREB was reported to linked to increased PI3K activity 
after activation of the ERKs and Akt signalling pathways [29-31]. Fujino et al. tested the 
phosphorylation of CREB after activation of EP2 and EP4 receptors and studied the activation of 
cAMP/PKA- and the PI3K-dependent signalling pathways. They showed that the mechanism of 
phosphorylating CREB is in EP2-expressing cells mostly cAMP/PKA-driven, while the 
mechanism in EP4-expressing cells involves a PI3K-dependent pathway. They further stated that 
stimulation of EP4 receptors via PGE2 negatively regulates the activity of PKA. Using H-89, a 
pharmacological inhibitor of PKA, it was shown that an inhibition of PKA decreases the 
phosphorylation of CREB in EP2-expressing cells, but not in EP4 [31]. However, Clarke et al. 
stated in 2005 [32] that H-89 is rather unsuitable as a tool for pharmacological research as it is 
quite non-selective. Instead, they transfected human airway smooth muscle (ASM) cells with an 
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adenovirus vector containing the PKA inhibitor, PKIα [32] and showed that EP2 and EP4 
signalling occurred via the PKA-pathway, not via the PI3K pathway [32]. These data question 
the involvement of the PI3K pathways in ligand-mediated cellular signalling via EP2/EP4 
receptors and further investigations are warranted. 
C. EP3 receptor   
1. Receptor 
Amongst all the EP receptor family members, the EP3 receptor is the only one known to express 
various isoforms [1]. It is understood that cows have four EP3- receptor isoforms called EP3A, 
EP3B, EP3C and EP3D [33]. The bovine EP3D is homologous to the human EP3D whereas the 
human EP3A receptor is a homolog of the mouse EP3α isoform [4]. Additionally, there are two 
more isoforms known in mice which are EP3β and EP3γ [33]. Rabbits express five isoforms 
named EP3-72A, EP3-74A, EP3-77A, EP3-80A and EP3-NT [34]. According to Israel and Regan [35], 
there have been ten different mRNA splicing variants identified in humans, resulting in eight 
different EP3 isoforms, named EP3-I, EP3-II, EP3-III, EP3-IV, EP3-V, EP3-VI, EP3-e and EP3-f [36]. 
Among the isoform EP3-I there are three different splice variants which vary in the 3′-
untranslated region, termed EP3-Ia, EP3-Ib and EP3-Ic. The nomenclature of the EP3 isoforms is not 
uniform and different publications have sometimes used different terms for the same isoform. 
Table 1 attempts to harmonize the nomenclature for the various EP3 receptor isoforms.  




according to Kotani et 
al. [38] [37] 
Nomenclature 
according to Schmid 
et al. [39] 
Nomenclature 
according to Regan 
et al. [4] 
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As detailed in Table 1, the EP3 isoforms differ in the amino acid sequence of the C-terminal 
region. Across the seven transmembrane helices of all EP3 isoforms, the first 359 amino acids are 
identical. However the carboxyl terminal of each isoform differs, being 6 to 65 amino acids long 
[40]. Thus, as a consequence of different mRNA splicing variants, the resulting protein isoforms 
have distinct signal transduction pathways [39].  
IRYHTNNYASSSTSLPC
QCSSTLMWSDHLER 
EP3-I EP3a EP3A 
VANAVSSCSNDGQKGQ
PISLSNEIIQTEA 
EP3-II EP3c EP3D 
EEFWGN EP3-III EP3b EP3E 








EP3-VI     
MRKRRLREQLICSLRTL
RYRGQLHIVGKYKPIVC 









In humans, the EP3 receptor isoforms can be Gi-, Gs-, Gq- or G12/13-coupled [35], with the main 
signalling pathway for EP3 considered to occur in a Gi-mediated manner [41]. Because of this, 
ligand engagement of the EP3 receptor (via either the endogenous ligand PGE2 or other EP3-
agonists) can result in a myriad of intracellular signalling pathways: some of these will be 
summarized below. 
One of the major outcomes of activation of the EP3 receptor is inhibition of adenylate cyclase 
and reduction of cAMP levels via Gi and enhancement of intracellular Ca
2+ [1, 41]. Schmid et al. 
[39] also reports that EP3a, EP3b and EP3c enhance Ca
2+ concentration and EP3d, EP3e and EP3f 
reduce cAMP via Gi.  
The MAPK pathway can also be activated via EP3 receptor isoforms. In cells transfected with 
human EP3A, PGE2 was shown to stimulate MAPK activity dose-dependently in a manner linked 
to Gi-protein activation [42]. The EP3-II and EP3-III receptors (expressed in HEK293 cells) can 
also trigger a MAPK-dependent transcriptional activation, although different signalling 
intermediaries are involved [35]. However, in contrast to the central role played by MAPK after 
activation of EP3-II and EP3-III, PGE2 activation of EP3-Ia caused a negligible phosphorylation of 
ERK [35].  
Other second messengers have also been shown to be involved in EP3 activation: i.e. engagement 
of EP3A1, EP3C and EP3D in primary human keratinocytes leads to an increase in diacylglycerol 
and ceramide production [43]. EP3 receptors have also been shown to be constitutively active 
although isoform specific differences exist: while EP3-I and EP3-II are not significantly 
constitutively active, EP3-III and EP3-IV do exhibit constitutive activity [40].  
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Small changes in amino acid sequence have also been shown to result in changes to signal 
transduction. For example, activation of the EP3-V and EP3-VI receptors (mainly detected in 
human uterus) results in production of cAMP via EP3-VI, but not via EP3-V receptor [36]. 
Interestingly, both receptors feature nearly the same amino acid sequence with the exception of 
nine amino acid residues [36] – see Table 1. The different carboxy termini of the EP3 isoforms 
have also an impact on the respective receptor’s internalization in response to PGE2. 
Furthermore, the isoforms are internalized by different mechanisms. Under influence of PGE2, 
the EP3-I receptor is internalized most rapidly and completely whereas EP3-II, EP3-V, EP3-VI and 
EP3f are only internalized to a certain extent. Moreover, EP3-II is internalized independently of β-
arrestin. Usually, β-arrestin binds to phosphorylated serine or threonine in the C-termimal tails. 
An explanation for why the EP3-III and EP3-IV isoform are not internalized could be due to their 
comparatively short carboxy termini and the absence of the amino acids serine and threonine 
[36]. The consequence of different rates of receptor internalization impacts on the physiological 
functions of the various members of the EP3 receptor isoform family [37].  
II. Selective and non-selective EP agonists and antagonists 
The design of potent and selective agonists and antagonists are essential research tools in 
prostanoid biology. For many years now, classification of the prostanoid receptors has been 
based mainly on the pharmacological actions of agonists and antagonists. However, in some 
cases, the selectivity of the pharmacological agents may have been limited. The following 
sections will summarize some of the commonly used agonists and antagonists for each member 
of the EP receptor family and provide an assessment of their selectivity. 
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A. EP1 receptor agonists and antagonists 
1. EP1 agonist: ONO-DI-004 
ONO-DI-004 [(17S)-2,5-ethano-6-oxo-17,20-dimethyl PGE1] from Ono Pharmaceuticals is a 
derivate of PGE1 and a selective EP1 agonist [44]. In CHO cells expressing EP receptor subtypes 
[45], the Ki values have been shown to be 0.15 µM for the EP1 receptor and >10 µM for other EP 
receptor subtypes. However, ONO-DI-004 appears to have only moderate affinity with the 
receptor, and its agonist effects have been demonstrated to be dependent on species and tissues.  
2. EP1 antagonist: ONO-8711 
ONO-8711 is a competitive antagonist at EP1 receptors that has been shown to inhibit PGE2-
induced increases in cytosolic Ca2+ concentration with inhibitory concentrations of 0.21 µM for 
mouse EP1 and 0.05 µM for human EP1 receptors [46]. In terms of pharmacological profile, 
ONO-8711 has Ki values of 1.7 nM at mouse EP1 and 0.6 nM at human EP1 receptors expressed 
in CHO cells, while Ki values of 67 nM for mouse EP3 and 76 nM for human TP receptors were 
reported. Ki values for other prostanoid receptors were >1,000 nM [46].  
3. EP1 antagonist: ONO-8713 
ONO-8713 is a selective EP1 antagonist that is similar to ONO-8711 but with greater selectivity 
for the EP1 receptor. Tested in CHO cells stably expressing different EP receptor subtypes, 
ONO-8713 has Ki values of 0.3 nM for both the human and mouse EP1 receptor and >1,000 nM 
for all other prostanoid receptors. This is in comparison to ONO-8711, where the Ki value for 
mouse and human EP1 receptor is 1.7 and 0.6 nM, respectively, and 67 nM and 76 nM for mouse 
EP3 and human TP receptor, respectively [46, 47]. Thus, ONO-8713 is more selective and potent 
than ONO-8711.  
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4. EP1 antagonist: GW848687X  
GW848687X is a potent and selective EP1 receptor antagonist developed by GSK. Due to its 
favourable profile in models of inflammatory pain it was selected as development candidate [48]. 
It is a competitive antagonist at the EP1 receptor with a pA2 of 9.1 and a selectivity >400-fold for 
EP1 receptor to other EP receptor subtypes, DP and IP receptors. It has 30-fold selectivity over 
the TP receptor, while not characterized at the FP receptor [48].  
5. EP1 antagonist: SC-51089 
SC-51089 is an acylhydrazide developed by the Searle group that was considered to be a 
potential clinical candidate as an analgesic but was subsequently dropped from the development 
pipeline when issues around its metabolism appeared, i.e. release of hydrazine [49]. In 
293E/CRE-SEAP reporter cells expressing human EP1 receptor, SC-51089 had a pKB value of 
6.9 (KB of 115 nM) but no activity at the DP receptor [50]. Abramovitz et al. [51] utilized 
radioligand binding assays in HEK293 cells expressing EP receptors and found Ki values of 
1,332±187 nM for EP1, 17,500 ±6,122 nM for EP3-IIII, 1,175 nM for TP and >100,000 nM for 
other prostanoid receptors [51]. These results are approximately one order of magnitude lower 
than that determined by Durocher et al. [50].  
6. EP1 antagonist: SC-51322 
SC-51322 is the most potent of the Searle series of EP1 receptor antagonists [52] with pKB values 
of 8.8 (KB of 1.60 nM) in 293E/CRE-SEAP cell reporter assays [50]) and a Ki value of 13.8 nM 
in the radioligand binding assay [51]. These are compared to Ki values of 698±122 nM for EP3-III 
and 507±47 nM for TP receptors, with Ki for other prostanoid receptors >10,000 nM. These data 
show that SC-51322 has high affinity for EP1 with a selectivity of 50-fold over EP3 and TP, and 
essentially no activity at the other prostanoid receptors.  
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7. EP1 antagonist: SC-19220 
SC-19220 is a dibenzoxazepine hydrazide derivative and one of the oldest prostanoid receptor 
antagonists. In 1971 Sanner et al. described the inhibitory effect of SC-19220 on PGE2-induced 
contraction of guinea pig isolated ileum [53]. At doses between 0.3 and 300 µM, SC-19220 acted 
as a competitive antagonist in isolated guinea pig gastric muscle [54]. SC-19220 was also shown 
to antagonize PGE2-induced contractions mediated by the EP1 receptor in guinea pig trachea 
[55]. In a radioligand binding assay in cells expressing the  human EP1 receptor [6], SC-19220 
was shown to compete for [3H]-PGE2-specific binding with an IC50 value of 6.7 µM. SC-19220 
has no binding affinity to human EP2 receptors expressed under the same conditions [11]. 
However, SC-19220 has no affinity for the mouse EP1 receptor, suggesting that there are some 
species differences [15]. 
B. EP2 receptor agonists and antagonists 
There are two main classes of EP2 receptor agonists available: those molecules that are 
structurally related to the endogenous ligand PGE2 (see 1-4) and the pyridyl-sulfonamines (see 5 
& 6). While EP2 receptor agonists have been available for some time, more selective and potent 
antagonists for the EP2 receptor have emerged recently.  
1. EP2 agonist: Butaprost 
Butaprost is one of the older synthetic EP2 receptor agonists, being less potent than the native 
PGE2 with a Ki of 2,400 nM [56]. In terms of selectivity, the Ki for EP1,3 and EP4 are higher than 
10,000 nM [56]. The ester group of butaprost is rather unstable and the free acid form metabolite 
is more potent (with an EP2 receptor Ki of 73); but butaprost does activate IP receptors as well 
[57]. The free acid and the methyl ester forms of butaprost have been shown to be 2- and 30-fold 
less potent than the natural ligand PGE2 at the EP2 receptor [56]. 
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2. EP2 agonist: 9b-Chloro-16-hydroxy-17,17-trimethylene-ω-nor-PGF2 
The 16-hydroxy-17,17-trimethylene 9beta-chloro PGF2 derivative, a product of Ono 
pharmaceuticals, has been reported to be a potent EP2 receptor agonist with Ki for the EP2 
receptor of 3.3 nM [58]. It is specific for EP2 receptors and shows nearly the same potency as 
PGE2 in functional assays [58, 59]. 
3. EP2 agonist: ONO-AE1-259 
ONO-AE-259 shows a high binding affinity for EP2 with Ki of 1.7 nM, a 22-fold higher affinity 
than PGE2 for the EP2 receptor. It also shows 700-1,500-fold selectivity for EP2 over other 
prostanoid receptors, namely EP1, 3, 4 and IP [58, 59]. This specific agonist is often used to define 
EP2 receptor-mediated effects experimentally in in vitro, ex vivo and in vivo models. For example 
in vitro, ONO-AE1-259 can increase cytosolic cAMP levels in human ASM cells and 
significantly inhibit ASM cell migration [60].  
4. EP2 agonist: AH13205 
AH13205 is a relatively non-selective EP2 receptor agonist with a comparatively low potency. 
Tani et al. published the following Ki values: EP1 receptor 2,800 nM, EP2 receptor 320 nM, EP3 
receptor 49 nM, EP4 receptor 2,200 nM [58]. Early studies by Nials et al. in 1993 [61] showed  
that AH13205 relaxes airway smooth muscle from cats and guinea pigs in vitro and works as a 
potent bronchodilator in guinea pigs on inhalation. Despite its promising preclinical profile it did 




5. EP2 agonist: CP-533536 
CP-533536 is a highly potent and selective EP2 agonist with a high binding affinity for the EP2 
receptor (Ki of 50 nM) and good selectivity, i.e. CP533536 is 16-fold higher selective for EP2 
than DP and 50 to 60-fold higher selective for EP2 to EP1, 3, 4 and IP receptors.. 
6. EP2 agonist: CP-544326 
CP-544326 is at least 270 times more selective for human EP2 receptors, compared to other 
human EP receptors: i.e. receptor affinity to EP2 is 10 nM, while the affinity to EP1,3 and EP4 is 
higher than 3,200 nM [62]. In rat and human cells expressing EP2, CP-544326-mediated cAMP 
production with average EC50 of 1.9 nM and 2.8 nM, respectively [62]. This was similar to that 
observed for PGE2 (EC50=2.6 nM) [62].  
7. EP2 antagonist: AH-6809 
AH-6809 is one of the longest used EP receptor antagonists. AH-6809, previously considered as 
an EP1 antagonist, was proven to have affinity to EP2 as well [63]. It was characterized as being 
non-selective, having similar affinity for EP2, EP3 and DP [51]. Abramovitz et al. [51] 
demonstrated the following binding affinities for AH-6809 in assays using HEK293 cells 
expressing EP receptors: Ki (EP1) 1,217±98 nM, Ki (EP2) 1,150±36 nM, Ki (EP3) 1,597±140 nM 
and Ki (DP) 1,415±104 nM. Despite the relatively weak antagonistic activity and a rather non-
selective profile, AH-6809 is commercially available and has been commonly used for probing 
EP2 receptor function, due to unavailability of other selective EP2 antagonists for some time.  
8. EP2 antagonist: PF-04418948 
PF-04418948 is azeditine-carboxylic acid derivative and selective EP2 antagonist developed by 
Pfizer. It has performed well in EP2 antagonist affinity and potency experiments in cell systems 
and in vivo analysis in rodent models [64]. Investigators reported that PF-04418948 inhibited 
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PGE2-induced increase in cAMP in cells expressing EP2 receptors with a functional Kb value of 
1.8 nM and also reversed PGE2-induced relaxation in the mouse trachea with an IC50 of 2.7 nM 
[64]. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow 
response in rats [64]. PF-04418948 is a EP2 selective antagonist (IC50 (EP2) is 16 nM while IC50 
(EP1, 3, 4, IP, DP) >10,000) [64] and the compound has  little activity against a diverse panel of 
GPCRs and ion channels at concentrations much higher than needed to antagonize EP2 receptors 
[65]. Birrell et al. [66] have also conducted further investigations that demonstrate the selectivity 
profile of PF-04418948 using functional bioassay systems. They tested PF-04418948 in a range 
of tissue-based assays to confirm selectivity against the native EP2 receptor: testing the EP2 
receptor in mouse and guinea pig isolated tracheal tissue, EP1-mediated responses of guinea pig 
isolated tracheal tissue, EP3 receptor-mediated responses of guinea pig isolated vagal tissue and 
EP4 receptor-mediated contraction of rat and human isolated tracheal tissue [66]. They showed 
that PF-04418948 only acted as an antagonist in EP2-mediated events, competitively inhibited 
relaxations of murine and guinea pig trachea induced by the EP2 agonist ONO-AE1-259 and the 
endogenous ligand PGE2. Notably, the affinity of the compound was not equal in the two 
preparations, the guinea pig trachea showed atypically low affinity compared to the mouse. The 
authors interpret the data as a question whether the guinea pig trachea is a usable EP2 receptor 
assay system [66]. In summary, PF-04418948 may be the long needed tool for further 
discoveries about the EP2 receptor, as research about this subtype of EP receptor was hampered 
due to the lack of a specific antagonist.  
9. EP2 antagonist: TG6-129, TG4-155, TG6-10-1 
Emory University has published a novel class of EP2 antagonists, structurally distinct from PF-
04418948. TG4-155 has an EP2 Schild KB of 2.4 nM and displays selectivity for EP2 over EP1, 
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EP3, EP4 and IP (550-4750-fold) but only 14-fold selectivity against the DP1 receptor.  TG6-10-1 
has an EP2 Schild KB of 17.8 nM and shows a 300-fold selectivity against EP3, EP4 and IP 
receptors, but only 100-fold selectivity against EP1, FP and TP receptors and only 10-fold 
selectivity against DP1 receptor [59, 67]. TG6-129 was developed by Emory University as 
another lead component for another class of EP2 antagonists. The compound shows 
nanomolecular potency and competitive antagonism for the EP2 receptor. Unlike TG4-155 and 
TG6-10-1, TG6-129 has shown high selectivity against DP1 (1660-fold) and EP4 receptors (440-
fold), but only 22-fold selectivity against the IP receptor [59, 68]. Although the selectivity of 
these compounds is not as high as PF-04418948, these compounds provide another option to 
further research about EP2 receptor and its role in health and disease. 
C. EP3 receptor agonists and antagonists 
Given that the EP3 receptor has a number of isoforms, many of the pharmacological studies 
designed to determine the selectivity and potency of agonists and antagonists against the EP3 
receptors have also explored the relative efficacy against some of the important isoforms.  
1. EP3 agonist: Sulprostone 
Sulprostone (16-phenoxy PGE2) is a synthetic selective EP1 and EP3 agonist [69]. In radioligand 
binding assays, performed in HEK293 cells expressing EP receptors, Sulprostone has Ki values 
of 0.35±0.11 nM for EP3-III, 198±10 nM for FP, 107±15 nM for EP1 and >7,740 nM for EP4, EP2, 
DP, IP and TP [51]. Okada et al. [70] examined the contractile actions of prostanoid analogues 
on longitudinal smooth muscles of the murine gastric fundus and ileum, where tensions induced 
by sulprostone (10 µM) were 126±5 and 95±5% respectively. These values were significantly 
greater than those induced by another EP3 agonist (ONO-AE-248: see 3 below), leading the 
authors to suggest that sulprostone may act on other receptors in addition to EP3 [70].  
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2. EP3 agonist: Misoprostol 
Misoprostol is a methyl ester analog of PGE1. Misoprostol (methyl ester) showed Ki values of 
10,249 ±1343 nM at EP2, 319±15 nM at EP3, 5,499±1102 nM at EP4 and 35,675±9,577 nM at 
EP1 receptors, while misoprostol (free acid) has Ki values of 34±5 nM at EP2, 7.9±1.0 nM at EP3, 
23±2 nM at EP4 and >10,000 nM at EP1 receptors: measured in radioligand binding assays, 
performed in HEK293 cells expressing EP receptors [51]. The de-esterification of misoprostol 
(methyl ester) produces drastic changes in the pharmacological profile with changes in affinity 
and selectivity for EP receptors:  affinity changes of at least 350-fold at EP2, 40-fold at EP3 and 
250-fold at EP4 receptors; modified selectivity from EP3 preferable to equipotent at EP2, EP3 and 
EP4 [51]. 
3. EP3 agonist: ONO-AE-248 
ONO-AE-248 is a selective EP3 agonist with close structural similarities to PGE2, being O-
dimethylated at position 11 and 15 [11,15-O-dimethyl-PGE2]. Binding affinities of ONO-AE-
248 were tested on CHO cells transfected with mouse EP-receptors 1-4 and have shown a Ki 
value of 15 nM for the mouse EP3 receptor. The Ki values for other mouse EP-receptors are 
>3,700 nM, confirming that ONO-AE-248 is specific for EP3. Furthermore, the agonistic activity 
of ONO-AE-248 at the EP3-receptor is 5.2 nM whereas it is >10,000 nM for the other three EP-
receptors [44]. ONO-AE-248 induced dose-dependent contractions in human pulmonary artery 
rings with pEC50 value of 6.34±0.35 [44]. In contrast, in human pulmonary veins, ONE-AE-248 
did not cause any contraction; this was considered due to the absence or presence of EP3 
receptors in the selected tissue [44]. In vitro, ASM cell migration, assessed by a chemotaxis 
assay, showed that ONO-AE-248 acts as a modest, but significant chemoattractant and enhancer 
of baseline cell migration [60]. 
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4. EP3 agonist: M&B28767 
M&B28767 is a relatively non-selective agonist for EP3. It shows best binding affinities to the 
human EP3 and EP4 receptors, but also binds to the other two EP receptors as well. Ki (EP1)=508 
nM, Ki (EP2)=1,370 nM, Ki (EP3)=0.3, Ki (EP4)=24 nM [71]. In vitro, Kiriyama et al. performed 
radioligand binding assays in CHO cells expressing mouse EP receptors, showing Ki values of 
0.68 nM for mEP3 receptor, while 120 nM and 124 nM for mEP1 and mFP receptors, 
respectively [15]. Perhaps M&B28767 demonstrates greater utility as a mEP3 receptor agonist? 
Accordingly, M&B28767 and sulprostone were compared in an experimental model examining 
morphine withdrawal ‘jumps’ caused by naloxone in morphine-dependant mice. M&B2767 
produced an inhibitory effect on morphine withdrawal jumps at lower doses than sulprostone 
[72]. M&B28767 can also exert differential effects on EP3 isoforms: M&B28767 was shown to 
increase basal cAMP level and inhibited the forskolin-induced increase in the cAMP level 
induced via EP3γ stimulation, while and decreasing both the basal and forskolin-elevated cAMP 
level induced through EP3α and EP3β [73]. 
5. EP3 agonist: TEI-3356 
TEI-3356 is an isocarbacyclin analogue and a selective antagonist for EP3 receptor. 
Pharmacological characterizations of TEI-3356 was performed with [3H]-PGE2 binding assays to 
test receptor affinity in CHO cells stably expressing EP receptors: TEI-3356 shows IC50 values 
of 33 nM for EP1, 450 nM for EP2 and 0.1 nM for EP3 on displacement of [
3H]-PGE2 binding 
and 90 nM for IP on displacement of [3H]-iloprost binding [74]. TEI-3356 (IC50= 0.01 µM) is 
stated as being a less potent EP3 agonist than M&B28767 (IC50= 0.001 µM), but showing higher 
selectivity for EP3 than M&B28767 [74].  
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6. EP3 agonist: GR63799X 
GR63799X was demonstrated in a radioligand binding assays performed in CHO cells 
expressing mouse EP receptors to have high selectivity for the mouse EP3 receptor with Ki values 
of 1.9 nM for mEP3 and 480 nM for the mEP4 receptors [15]. 
7. EP3 antagonist: ONO-AE3-240 
ONO-AE3-240 was developed by Ono Pharmaceuticals as a selective EP3 antagonist. Binding 
affinities were tested with radioligand competition-binding assays and Amano et al. have 
published Ki values for EP1 (590 nM), EP3 (0.23 nM), EP4 (58 nM), FP (1,500 nM) and >10,000 
nM for EP2, DP, TP and IP [75]. This selective antagonist has been used to implicate a role for 
EP3 receptor-mediated signalling in tumor development and angiogenesis. This was 
demonstrated in mice, where subcutaneously injected dilutions of ONO-AE3-240 inhibited 
tumour growth and angiogenesis in a sarcoma model typified by new vessel growth [75].  
8. EP3 antagonist: L-826266 
L-826266 is a selective EP3 antagonist from Merck Frosst, Canada. Maher et al. have shown that 
PGE2 mediates cough via the EP3 receptor using a range of in vitro and in vivo techniques 
utilizing the EP3 receptor antagonist L-826266 [76]. In vivo studies showed that L826266 
attenuated the depolarization to PGE2 in the isolated guinea pig vagus nerve and significantly 
inhibited the PGE2-induced depolarization of mouse vagus nerve (64.8±2.8%), while also 
showing similar effects in human vagus nerve [76]. Guinea pigs were exposed to an aerosol of 
PGE2 in in vivo studies, where the use of EP3 antagonist L826266 significantly decreased the 
number of coughs in response to aerosolized PGE2 [76]. However, L-826266 is unable to 
distinguish between the EP3 receptor splice variants, according to Oliva et al. [77]. 
25 
 
9. EP3 antagonist: CM9 
Binding studies performed with CM9 in a wide range of cells, including human osteosarcoma 
cells expressing human EP3C and EP3E and DP receptors, rat EP3A and EP3C receptors as well as 
CHO cells expressing hEP3A, hEP1, hEP2 and hTP receptors and HEK293 cells expressing  hEP4, 
hFP and hIP receptors. Collectively, these data demonstrate that CM9 shows Ki values of 
0.21±0.17 nM in hEP3A, 0.24 nM in hEP3E, 0.25±0.03 nM in rEP3A, 0.78±0.17 in rEP3C and 570 
nM in hTP.  Ki values of CM9 on the other prostanoid receptors are >2,390 nM [78]. These data 
shows that CM9 is a suitable tool for the evaluation of a broad range of EP3 receptor isoforms. 
10. EP3 antagonist: DG-041 
DG-041 is selective EP3 antagonists developed by deCODE Chemistry to serve as a novel 
antiplatelet agent, as it shows significant antiplatelet activity with only minimal impact on 
bleeding time. In vitro pharmacology was published by Singh et al. [79]: DG-041 shows good 
selectivity in radioligand [3H]-PGE2 displacement binding assay with IC50 values of 4.6 nM for 
EP3, 4,169 nM for EP2, 8,039 nM for EP4, 14,414 nM for IP and >20,000 nM for EP1. Thus, DG-
041 shows more than 1,000-fold selectivity for the EP4 receptor over other prostanoid receptors 
[79].  
D. EP4 receptor agonists and antagonists  
The discovery and utility of selective EP4 agonists and antagonists has advanced since 2000, 
when Abravotiz et al. stated “there are no selective agonists or antagonists for EP4…” [51]. 
Today, there are many selective EP4 agonists and antagonists commercially available and these 
will be summarized below. 
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1. EP4 agonist: TCS2510 
TCS2510 was developed in the early 2000’s by the Merck Frosst as a chemically modified 
analogue of PGE2 containing a lactam and a tetrazole structure [80].  Billot et al. [80] measured 
potency and selectivity over other prostanoid receptors in HEK293 transfectants and measured 
binding properties in cell cAMP assays. The Ki of TCS2510 for the EP4 receptor was 1.2±0.2 
nM, while the Ki to the other prostanoid receptors was >13,000 nM. TCS2510 is a full agonist in 
the cell efficacy assay with an EC50 of 2.5±1.0 nM, and this was comparable to the EC50 of PGE2 
itself (EC50=3.0± 0.4 nM) [80]. 
2.  EP4 agonist: Compound 9b 
Serono Research Institute published and tested analogs of PGE2 with introduction of diene 
groups at the ω-side chain [81]. Using receptor binding assays on membranes prepared from 
HEK293 cells expressing EP1-4 receptors, they identified compound 9b as having potency for the 
EP4 receptor (Ki= 4 nM, EC50= 0.1 nM), but also affinity to the EP2 receptor (Ki=60 nM, 
EC50=35 nM). Compound 9b had low affinity for EP1 and EP3 receptors (both Ki> 10,000 
nM)[81]. 
3. EP4 agonist: ONO-AE1-734 
Competitive radioligand binding assays performed by Kabashima et al. [82] measured the Ki 
values for ONO-AE1-734 as 0.7 nM for EP4, 56 nM for EP3, and 620 nM for EP2. The rest of the 
prostanoid receptors have Ki more than 10,000 nM [82]. 
4. EP4 agonist: ONO-AE1-329 
ONO-AE1-329 is selective agonist of the EP4 receptor that is widely used in research. In 2000, 
Suzawa et al. tested binding affinities of different EP receptors expressed in CHO cells and 
reported: Ki (EP1)>10 µM, Ki (EP2)=2.1 µM, Ki (EP3)=1.2 µM, Ki (EP4)=0.0097 µM [45]. A 
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number of the experimental models have examined the efficacy of ONO-AE1-329 as a relaxant, 
but species differences exist. ONO-AE1-329 caused relaxation of human airway muscle 
(76.2±8.6% of maximum relaxation to 100 mM papaverine) with a pKi for the EP4 receptor of 
8.0 [83]. Benyahia et al. showed similar effects of ONO-AE1-329; it induced potent relaxation 
of human bronchial preparations (pEC50=7.0±0.3) and vasodilatation in human pulmonary veins 
[84]. The compound was also able to cause substantial relaxation of rat tracheal strips 
(36.7±4.0% of maximum relaxation to 100 µM papaverine) [83]. Notably, EP receptor-mediated 
relaxation of human airway muscle differs compared to the animal models. While bronchial 
relaxation in guinea pigs, mice and monkeys relies more on EP2-receptor signals, while human 
and rat bronchial relaxation is mediated via EP4 receptor [83]. ONO-AE1-329 has also been used 
on cells: Luschnig-Schratl et al. have shown that ligation of EP4 receptors can inhibit eosinophil 
function [85], while Aso et al. have demonstrated that it enhanced release of IL-8 by human 
pulmonary microvascular endothelial cells via EP4 [86]. 
5. EP4 agonist: L-902688 
L-902688 is a selective EP4 agonist that was shown to relax human bronchial muscle (pEC50= 
7.8±0.2) and induce dilatation of human pulmonary vein preparations [84]. Used in experiments 
by Foudi et al. [87] L-902688 induced potent vasodilatation of the human pulmonary vein in 
manner similar to that of the native ligand PGE2 (pEC50=8.1± 0.1 compared to pEC50=7.2±0.2, 
respectively). The introduction of a 6-tetrazole ring to the molecule prevents β-oxidation [88]. 
6. EP4 antagonist: ONO-AE3-208 
ONO-AE3-208 has Ki values obtained by a competitive radioligand binding assay of: 1.3 nM for 
EP4, 30 nM for EP3, 790 nM for FP, 2.400 nM for TP and more than 10,000 nM for the other 
prostanoid receptors [82]. It has been shown to be an effective EP4 antagonist in functional 
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assays as ONO-AE4-208 was able to inhibit relaxation of human airway muscle caused by PGE2 
and the EP4 agonist ONO-AE1-329 (pA2=8.1±0.2 and 8.8±0.3, respectively) [83]. 
7. EP4 antagonist: GW627368X 
GW627368X is a benzene sulphonamide developed by GSK and characterized as a potent and 
selective antagonist of EP4 receptors with additional human TP receptor affinity [89]. The 
compound is reported to be without any agonist or antagonist activity for prostanoid EP2, EP3, IP 
and FP receptors, and while binding to human prostanoid TP receptors, but not to the TP 
receptors of other species.  
8. EP4 antagonist: AH23848 
AH23848 has been widely used as an EP4 antagonist and played an essential role in the early 
pharmacological definition of the EP4 receptor.  In competitive binding assays performed in 
2000, it was shown to have a Ki of 2,690±232 nM for EP4 [90]. More recently it was confirmed 
to have a comparatively low affinity antagonist at both the EP4 and TP receptors (pKi 4.9-5.6 and 
6.2, respectively) [83]. Although it was the prototype of EP4 antagonist its use has been largely 
overtaken by more selective and potent antagonists [88]. 
9. EP4 antagonist: CJ-023423 
CJ-023,423 is a potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic 
properties from Pfizer. In radioligand binding studies using membranes prepared from HEK293 
cells stably expressing human EP4 or rat EP4 receptors, CJ-023,423 displaced [
3H]-PGE2 binding 
with an IC50 value of 14±4 nM  and 27±1 nM , respectively [91]. CJ-023,423 was 200-fold more 
selective for the human EP4 receptor than other prostanoid receptors, showing IC50 >20 µM for 
EP1, 2, 3, FP, IP and TP and IC50 of 4.3 µM for DP [91]. These results suggest that CJ-023,423 is a 
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competitive antagonist for human and rat EP4 receptors and in in vivo, orally given doses of CJ-
023,423 reduced thermal hyperalgesia induced by intraplanar injection of PGE2 [91]. 
10. EP4 antagonist: CJ-042794 
Pfizer’s CJ-042794 could be seen as an improvement on CJ-023423 based on potency. In in vitro 
pharmacological characterization utilizing binding assays in membrane samples of HEK293 cells 
overexpressing human EP receptors CJ-042794 displaced [3H]-PGE2 binding to each receptor 
EP1, EP2, EP3, and EP4 at 5.0 nM, 5.5 nM, 2.8 nM, and 0.4 nM, respectively, and the binding 
affinity of CJ-042794 was at least 200-fold more selective for human EP4 receptor than for other 
human receptors [92]. Moreover, when the selectivity of the antagonist was tested toward 63 
proteins, CJ-042794 did not show any affinity to these GPCRs, transporters and ion channels 
[92].  
11. EP4 antagonist: MF-766 
MF-766 was designed by Merck Frosst and Colucci et al. [93] utilised the rat adjuvant-induced 
arthritis model to demonstrate in vitro potency and selectivity: high affinity at the EP4 receptor 
(Ki 0.23 nM) and good selectivity against other prostanoid receptors with 7,000-fold higher 
affinity for EP4 receptors (closest was DP1 with a Ki of 1,800 nM). It has shown to be a full 
antagonist with an IC50 of 9.5 nM in the functional assay and the affinity to the EP4 receptor (i.e. 
Ki 0.23 nM) was not significantly shifted in the presence of 10% human serum (Ki now 0.34 
nM). The authors also evaluated the pharmacokinetic profile in rats and beagle dogs and MF-766 
showed good pharmacokinetic properties with high oral bioavailability (74-86%) and low to 
moderate clearance rate (half-life was between 2.6 and 4.6 hours) [93]. 
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12. EP4 antagonist: L-161982 / EP4A 
L-161982 (also known as EP4A) contains a diaryl-acylsulfonamide structure and in radioligand 
binding assays in HEK293 cells expressing human and rat EP4 receptors have binding affinities 
(Ki) of 0.024 µM and 0.032 µM, respectively [94]. Affinities (Ki) to the other EP receptors are 
1.9 µM for human EP3 and 0.7 µM for human TP receptors: this shows a selectivity of roughly 
30-fold for the human EP4 receptor. L-161982 is at least 200-fold more selective for rat EP4 than 
the other rat EP receptor subtypes [94].  L-161982 has been utilized to implicate a role for EP4 in 
bone anabolic effects of PGE2 in RP-1 periosteal cells [95]. Clarke et al. have used L-161982 as 
a pharmacologically active antagonist in human airway smooth muscle cells to inhibit the 
augmentation of cytokine release by EP4 agonism [32]. 
13. EP4 antagonist: BGC20-1531 
The pharmacological characterisation of BGC20-1531 was published in 2009 [96] and showed 
that BGC20-1531 was able to displace [3H]-PGE2 from human recombinant EP4 receptor with a 
pKi of 7.9±0.1. This antagonist showed negligible affinity to other prostanoid receptors: 
measured pKi values were EP1 < 5, EP2 < 5, EP3 < 5, EP4 7.9, TP < 5, DP 5.6 and IP < 5, 
showing that BGC20-1531 has good affinity and selectivity for the human recombinant EP4 
receptor [96]. The affinity and potency demonstrated in cell lines expressing human EP4 
receptors (pKi=7.9 and pKb=7.6) were comparable with the results of the ex vivo assays (pKb= 
7.6 - 7.8).  
III. Transgenic mice 
A real step-change in the field commenced when transgenic mice in which the genes for each of 
the four EP receptors has been knocked-out began to be utilized in the respiratory context. The 
Narumiya lab from Kyoto University [19] were first to generate the mice by homologous 
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recombination [97] and the mice known as  Ptger1-/- , Ptger2-/- , Ptger3-/- , Ptger4-/-  lack the EP1, 
EP2, EP3 and EP4 receptors. The first reports that used in the respiratory space came in Maher et 
al. [76], who combined a pharmacological approach (using selective EP3 receptor antagonists) 
and prostanoid receptor–deficient mice to clearly implicate the EP3 receptor as mediating PGE2-
induced cough. Since that time, these mice have been used in a number of key studies that 
provide notable in vivo proof-of-concept data. For example, prostanoid receptor-deficient 
transgenic mice have been used to show that EP4 receptor activation is responsible for the anti-
inflammatory activity of PGE2 [98] and to implicate EP2 and EP4 receptors in PGE2-induced 
microvascular leak [99]. Further studies that utilize these mice are warranted. 
IV. Role and function of EP receptors in lung health and disease 
EP receptors have been identified in playing a critical role in chronic respiratory diseases, 
including asthma and COPD. In the following sections we will highlight some notable examples 
where EP receptor agonists and antagonists, or prostanoid receptor-deficient mice, have been 
utilized to implicate EP receptors in pathophysiological processes in respiratory conditions. 
Moreover, these tools have highlighted novel pharmacotherapeutic strategies and targets that 
could yield beneficial outcomes in the future. 
A. Migration of airway smooth muscle cells 
In addition to regulating airway calibre and mediating bronchospasm, ASM cells fulfil different 
tasks such as proliferation resulting in hypertrophy and hyperplasia, as well as contribution to 
airway inflammation through the synthesis of a range of different mediators [100]. A subset of 
EP receptors has been demonstrated as being present in human ASM cells: i.e. the mRNA of 
EP2, EP3 and EP4 are detected in human ASM cells, while EP1 mRNA was not represented in 
this type of cells [101-103]. Migration is also an important function of ASM cells that may have 
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significant impact on asthma pathogenesis. PGE2, and the selective EP2 agonist ONO-AE1-259 
and EP4 agonist ONO-AE1-329 were shown to decrease migration of human ASM cells induced 
by platelet-derived growth factor BB in vitro [60]. This process occurs via activation of 
cAMP/PKA. Thus, it follows that since activation of EP2 and EP4 receptors attenuate ASM cells 
migration [60], selective EP agonists may represent novel pharmacotherapeutic strategies to 
reverse or prevent development of airway remodelling in asthma. 
B. Airway microvascular leak 
Airway microvascular leakage has been clinically shown to be an early sign of asthma 
impairment, even when no signs of inflammation, such as increased cellular influx, had yet 
developed [104]. Moreover microvascular leak has also been shown to exist in COPD [105]. In 
2016, Jones et al. [99] utilized mouse and guinea pig allergic asthma models to demonstrate the 
influence of EP2 and EP4 receptors on microvascular leakage. Activating the EP2 and EP4 
receptors with PGE2, or selective agonists ONO-AE1-259 (EP2) and ONO-AE1-329 (EP4) 
induces microvascular leakage. In contrast, the response to PGE2 was greatly decreased when the 
EP2 and EP4 receptor was knocked out in Ptger2
-/- and Ptger4-/- mice, respectively [99]. 
C. Pulmonary blood vessels 
By engaging with different prostanoid receptors, prostaglandins can exert differential effects in 
the pulmonary vasculature, including both vasoconstriction [106] and vasorelaxation [87]. 
Among the four EP receptors, only EP1 and EP4 were found in smooth muscle cells of human 
pulmonary veins [87]. Vasoconstrictive activity of EP1 receptors was proven by use of 17-
phenyl-PGE2, sulprostone (a non-selective EP1 and EP3 agonists) and iloprost, a PGI2 analogue 
and agonist at the IP-and EP1 receptors. The antagonist AH6809 (DP/EP1/EP2 receptor 
antagonist) and SC19220 (EP1 antagonist) reversed the agonists’ effect on human pulmonary 
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veins [106]. Additionally, EP1 antagonists (ONO-8711, ONO-8713) reversed sulprostone-
induced contractions in human pulmonary vessels [44]. On the other hand, the selective EP4 
agonists ONO-AE1-329 and L-902688 induced relaxation of human pulmonary veins while the 
selective EP4 antagonist GW627368X led to vasoconstriction. Thus, it follows that EP2 receptors 
induce vasoconstriction [44, 106], and EP4 receptors mediate vasorelaxation in human 
pulmonary veins [87], although other non-EP prostanoid receptors are involved. The situation is 
different in human pulmonary arteries where vasoconstriction is mediated via EP3 and TP 
receptors. This was confirmed by the use of the EP3 agonist ONO-AE-248 and the TP-antagonist 
BAY u3405 [44].  
D. Mast cell degranulation 
Mast cells are recruited to the lung in asthma and are critical for the initiation and perpetuation of 
inflammation and disease pathogenesis [107-109]. Mast cells degranulate in an asthma attack in 
an IgE-mediated manner and notably, PGE2 has been shown to inhibit IgE-mediated release of 
histamine in cultured human lung mast cells (HMLC) in vitro [110]. More precisely this process 
is mediated via activation of the EP2 receptor. This was proven in experiments using several EP 
agonists and antagonists where only the EP2 agonist butaprost was able to inhibit histamine 
degranulation from HLMC whereas sulprostone (EP1/EP3 agonist), 17-phenyl-trinor-PGE2 (EP1 
agonist) and agonists of DP, FP, IP or TP failed to inhibit the histamine release [111]. AH6809 (a 
DP, EP1, EP2 antagonist) was able to antagonize the inhibitory effect of PGE2. The EP4 
antagonist AH23848 did not succeed in inhibiting the effect of PGE2 on HLMCs [111]. In 2013, 
Kay et al. extended their earlier study to reappraise the effects of PGE2 on HLMC degranulation 
because at this point in time more selective EP2 and EP4 agonists and antagonists were available. 
Non-selective (PGE2, Misoprostol), selective EP2 agonists (ONO-AE1-259, AH13205, 
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butaprost-free acid), selective EP2 antagonists (PF-04418948, PF-04852946), selective EP4 
agonists (L-902,688, TCS251) and selective EP4 antagonists (CJ-042794, L-161,982) were 
utilized in the study [112]. The outcome was that while IgE-dependent histamine release in 
HLMC can be mediated by both EP2 and EP4 receptor, EP2 receptor-mediated release 
predominates. A number of other interesting observations were made in this study [112]: the EP2 
selective receptor agonist ONO-AE1-259 behaved as a partial agonist relative to PGE2; HLMCs 
express mRNA for EP2 and EP4 receptors, while the human mast cell line LAD2 doesn’t and 
expresses EP3 instead; and the inhibitory effect of selective EP4 agonist L-902,688 could not be 
reversed by specific EP2 and EP4 antagonists leading to the conclusion that L-902,688 influences 
the degranulation of HLMC via another unknown mechanism [112].  
In 2015, Säfholm et al. [113] investigated the relationship between mast cell degranulation and 
bronchoconstriction in human small airways ex vivo in order to more directly investigate the 
correlation between mast cell activity and muscular bronchial activity. Säfholm et al. used intact 
sections of human small airways in order to mirror the processes in the human body more 
precisely and showed that PGE2 mediates bronchorelaxation via EP4 receptor and 
bronchoconstriction via the TP receptor. Furthermore, PGE2 inhibits IgE-mediated release of 
histamine and other mediators. Using the EP2 receptor antagonist PF-04418948 it was shown that 
the inhibiting effect of PGE2 on mast cell degranulation occurs via activation of EP2 receptors 
[113]. These ex vivo studies, in part, mimic the in vitro analyses where EP2 receptors were shown 
to play an important role [111, 112].  
A further study describes a protective role for PGE2 in exercise-induced bronchoconstriction. 
Because of hyperventilation while exercising a loss of airway water occurs leading to a higher 
osmolality in the bronchi. This augmented osmolality in airway surface liquid is thought to cause 
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activation of mast cells and subsequent bronchoconstriction [114]. To mimic the effects of 
exercise on airway fluid osmolarity, mannitol was used as a hyperosmolar stimulus [114, 115]. 
Utilizing the EP2 (AH6809) and EP4 (AH23848) antagonists, PGE2 was shown to prevent 
hyperosmolar mast cells activation via EP2 and EP4 receptors [115]. Taken together, we can 
conclude that EP2 and EP4 agonists can exert beneficial actions in exercise-induced 
bronchoconstriction by reduction of human mast cell activity caused by higher osmolarity in the 
bronchi [115].    
E. Bronchodilatation 
In human airways, inhalation of PGE2 results in a bronchodilatation [116]. Excitingly, the 
selective EP4 receptor agonist ONO-AE1-329 can also lead to relaxation of human airways [83]. 
Moreover, the selective EP4 receptor antagonist ONO-AE3-208 reversed the bronchodilatation 
achieved with PGE2 and ONO-AE1-329. The same was observed in rat trachea [83]. In other 
species, specifically guinea pig, mouse and monkey, relaxation of trachea was mediated by the 
EP2 receptor. This emphasizes important species differences and underscores that processes in 
animal models are not always congruent with processes in the human body [83].  
The role of EP4 receptors in mediating bronchodilatation was confirmed in human bronchial 
preparations by Benyahira et al. [84], where histamine-induced contraction could be reversed by 
the selective EP4 agonists ONO-AE1-329 and L-902688. In addition, the specific EP4 antagonist 
GW62768X blocked PGE2-induced relaxations of human bronchial preparations which were pre-
contracted with histamine [84]. 
However, the conclusions made in Buckley et al. [83] and Benyahia et al. [84] differ from that of 
Norel et al. [117] who showed that PGE2-induced relaxation of human airway tissue could not be 
reversed by the EP4 antagonist AH23848B. Instead AH6809 (DP, EP1, EP2-receptor antagonist) 
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decreased bronchodilatation [117].  This is good example that clearly shows the importance of 
using selective pharmacological tools to implicate a particular EP receptor and how better 
reagents have become available over time.  It has to be remarked that the later studies [83, 84] 
had more specific EP receptor agonists and antagonists available than Norel et al. [117]. The 
specific EP2 receptor agonists AH13205 and ONO-AE1-259, as well as specific EP4 agonist 
ONO-AE1-329, L-902688 and selective EP4 antagonist ONO-AE3-208 and GW627368X were 
applied [83, 84]; whereas Norel et al. used Misoprostol, AH23848B (TP, EP4 antagonist) and 
AH6809 (DP, EP1, EP2 receptor antagonist) which are not as specific [117]. 
F. Cough 
Inhaled PGE2 induces cough in humans [118, 119]. Maher et al. [76] utilized  a sensory nerve 
activation model using isolated vagus nerves of human, guinea pig and mouse to show that 
depolarization after PGE2 challenge indicated cough. When the isolated vagus nerves of guinea 
pigs were exposed to the selective EP3 antagonist L826266, PGE2-mediated depolarization due 
was attenuated. These data demonstrate that cough induced by PGE2 mediated via the EP3 
receptor [76]. More recently, the Transient Receptor Potential (TRP) family of ion channels has 
been implicated as playing an important role as the common effectors of the cough response 
[120, 121] and TRP channels represent novel therapeutic targets. 
G. Angiogenesis  
Airway remodelling in asthma is typified by increased vascularization due to angiogenesis. This 
is promoted through production of vascular endothelial growth factor (VEGF) in airway resident 
cells. VEGF production is regulated by prostanoids. In human ASM cells, the expression of 
VEGF-A was increased by activation of EP2 and EP4 via PGE2, ONO-AE1-259 and ONO-AE1-
329 [102]. In human lung fibroblasts, Huang et al. [122] employed butaprost, ONO-AE3-248 
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and ONO-AE1-329 to come to the conclusion that PGE2 induces apoptosis via activation of EP2 
and EP4 receptors. Also in lung fibroblasts (human fetal), PGE2 activation of the EP2 receptor 
was shown to results in stimulation of VEGF production [123]. The researchers demonstrated 
that the interaction between the phosphodiesterase 4 inhibitor roflumilast with either PGE2, 
ONO-AE1-259-01 (EP2 agonist), or ONO-AE1-329 (EP4 agonist), lead to an enhancement of 
VEGF production. The stimulatory effect of PGE2 on VEGF production could be significantly 
inhibited by EP2 antagonist AH6809. Nevertheless, a significant block of the stimulatory effect 
of roflumilast could only be achieved by combining EP2, EP3 (ONO-AE3-240) and EP4 (ONO-
AE3-208) antagonists. These data reinforce the notion that EP2 and EP4 receptors, and possibly 
the EP3 receptor, are involved in the stimulatory effect of roflumilast in the presence of PGE2. A 
further discovery was that the EP1 antagonist ONO-8713 enhanced the VEGF release in presence 
of control media and PGE2 suggesting that activation of EP1 receptor could possibly stop VEGF 
release [123].  
H. Senescence 
Cellular senescence is considered a pathogenic feature of COPD [124]. An investigation of lung 
fibroblasts from COPD patients, smokers and non-smoker controls showed that lung fibroblasts 
of COPD patients express a higher amount of EP2 and EP4 receptors [125]. This was 
demonstrated via the use of several EP2 and EP4 receptor agonists (ONO-AE1-259) and 
antagonists (AH6809, PF-04418948, GW627368X, L-161982) which mimicked and accordingly 
reversed the effect of PGE2 on lung fibroblasts. Furthermore, fibroblasts from people with COPD 
demonstrated enhanced senescence markers, as well as augmented COX-2, PGE2, cytokine, 
chemokine, and matrix metalloproteinase expression. Notably, through enhanced PGE2 
secretion, senescent COPD lung fibroblasts exerted autocrine and paracrine effects on non-
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senescent COPD lung fibroblasts via activation of the EP2 and EP4 receptors. This potentiating 
feedback loop leads to reinforcement and propagation of senescence and implicates a central role 
for prostanoids/EP receptors in COPD [125].  
I. Airway inflammation 
Inflammation drives disease progression and pathogenesis in several lung diseases and studies 
have shown that these pathways are driven via EP receptor ligand engagement. Of particular 
importance are the EP2 and EP4 receptors, predominately due to their links to adenylate cyclase 
and the ability to increase intracellular cAMP [126]. This has been demonstrated in in vitro and 
in vivo models of airway inflammation. In ASM cells, we [127] and others [128-131] have 
shown that mediators that increase cAMP (including PGE2) can modulate cytokine expression in 
vitro. In 2000, we showed that PGE2 increased cAMP in ASM cells and that this augmented 
cAMP has differential effects on cytokines: some were repressed, while some were augmented 
[127]. We [132] went onto to show that the outcome of cAMP elevation on the synthetic 
function of ASM cells could be explained by an understanding of the transcriptional regulation 
of the cytokine, viz whether the cytokine has a CRE in its 5′-promoter region (e.g. IL-6 does and 
hence cAMP alone will increase IL-6 secretion).  Two studies by Clark et al. [101, 129] also 
showed that the impact of PGE2 on airway inflammation in vitro could vary depending on 
cytokine examined. Clark et al. [129] demonstrated that the IL-1β-induced release of GM-CSF 
could be suppressed by PGE2, ONO-AE1-259 (selective EP2 agonist) and other non-selective 
EP2 agonists, while the reverse was observed for EP2 antagonist AH6890 but not for EP4 
antagonists (AH23848B, L-161,982). These findings lead to the conclusion that the release of 
GM-CSF can be inhibited by PGE2 through activation of the EP2 receptor [129]. A similar study 
investigating G-CSF discovered that PGE2 increases elaboration of G-CSF which was promoted 
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by IL-1β. This transaction is performed by both EP2 and EP4 receptors. AH6809 (DP, EP1, EP2 
antagonist) and L-161,982 (EP4 antagonist) were not able to inhibit the PGE2 induced G-CSF 
release completely. Both EP antagonists had to be added in combination in order to realize an 
effective antagonism [101].  
However, in more recent studies we have shown that cAMP elevation can also increase anti-
inflammatory proteins, namely, the MAPK deactivator and anti-inflammatory protein, MAPK 
phosphatase 1 (MKP-1) [133]. MKP-1upregulation is a common response to elevated cAMP 
induced by a diverse range of stimuli. In ASM cells we have shown that inflammatory stimuli 
[134], cAMP elevating agents [133], as well as respiratory medicines such as β2-agonists [133, 
135] and phosphodiesterase 4 inhibitors [136, 137], can all increase MKP-1 via CREB-mediated 
pathways and perhaps offset the impact of cAMP on cytokine production. In 2016, we used 
selective antagonists of EP2 (PF-04418948) and EP4 receptors (GW 627368X) to show that PGE2 
increases production of the anti-inflammatory protein MKP-1 via cAMP/CREB-mediated 
cellular signalling in ASM cells and that EP2 may, in part, be involved, although further studies 
are warranted [138] 
Other cellular models of airway inflammation have been utilized to demonstrate the impact of EP 
receptor engagement in the respiratory context. Taking macrophages as a key example with 
relevance to lung disease, Takayama et al. [94] showed that activation of the EP4 receptor of 
human macrophages via PGE2 leads to an inhibition of cytokine production, including IL-8. 
More recently, Gill et al. [139] evaluated the effects of EP2 selective (PF-04852946, PF-
04418948) and EP4 -selective (L-161,982, CJ-042794) receptor antagonists on PGE2 responses. 
They confirmed that the anti-inflammatory effects of PGE2 on human lung macrophages are 
mediated by the EP4 receptor [139]. 
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In mice, intranasal lipopolysaccharide (LPS) challenge enhanced the neutrophil infiltration in 
bronchoalveolar (BAL) fluid which was reversed by additional application of PGE2 or PGE2 
analogue misoprostol [140]. The reduction of neutrophils by PGE2 was mimicked by EP4 
selective agonist ONO-AE1-329 and blocked by the EP4 receptor antagonists GW627368X or 
ONO-AE3-208. LPS-induced pulmonary vascular leakage was reversed by PGE2 or ONO-AE1-
329 (specific EP4 receptor antagonist). Hence the conclusion drawn was that the infiltration of 
neutrophils in in vivo models of airway inflammation can be inhibited by activation of EP4 
receptors [140]. 
Finally, the in vivo studies with the prostanoid receptor–deficient mice have been conducted.  In 
2015, Birrell et al. [98] performed murine respiratory models with EP1-4 receptor knock-out mice 
(Ptger1-4-/-), challenged either with LPS (as an innate stimulus), ovalbumin (as an allergic 
response, mimicking asthma) or cigarette smoke (as an inhaled pollutant, mimicking COPD). 
The outcome of this experiment was that increased levels of eosinophils (especially in 
ovalbumin-challenged mice) and elevated levels of neutrophils in LPS and smoke treated mice 
were found in the BAL of Ptger4-/- mice. There were no significant changes in the number of 
inflammatory cells found in the BAL in the EP1-3 receptor knock-out mice. Coupled with cell-
based assay systems, where murine and human monocytes were treated with LPS to stimulate 
cytokine production, PGE2 exerted a concentration-dependent repression. The repressive effects 
of PGE2 could be mimicked by the selective EP4 agonist ONO-AE1-329 but not by the selective 
EP1-3 agonists ONO-D1-004, ONO-AE1-259 and ONO-AE-248.  These findings led the authors 
to assert that PGE2 activated EP4 receptors in the lung exert anti-inflammatory effects [98]. 
V. Summary and future directions 
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Targeting EP receptors represent a fast developing sector in research, especially in lung health, 
with exciting scope for development of efficacious pharmacotherapeutic agents in the future. The 
discovery of specific means to manipulate the EP receptor with agonists and antagonists, or 
through the use of genetically-modified prostanoid receptor–deficient mice, has resulted in more 
precise research results whereby the individual functions of EP receptors in specific tissues have 
now been clearly defined. A key example is the EP4 receptor that has been now firmly 
entrenched as a target to induce bronchodilatation [83] and reduce inflammation [98]. Another 
key message that has emerged is the species differences in EP receptor-mediated cell signalling 
pathways. This is best highlighted in the example of the EP2 receptor, where selectivity profiling 
and functional bioassays demonstrate distinct differences between commonly-used experimental 
models [66].  
In summary, PGE2 is an important bioactive prostanoid that has both ‘bad’ and ‘good’ effects 
because of myriad interactions with EP1-4 receptors [3]. With the advent of more selective means 
to target individual EP receptors, comes the opportunity to precisely promote the beneficial 
effects of prostanoids while minimizing the unwanted effects. Although research challenges 
remain (such as understanding how the prostanoid receptors themselves are upregulated or 
desensitized, and the impact of cell signalling cross-talk on functional outcome), there is no 
doubt that novel and specific molecules targeting individual prostanoid receptors (or even 
isoforms) may represent efficacious drug entities in the future. Drug delivery through 
aerosolization technology may enable us to deliver these novel medicines (alone or in 
combination with current medicines) to the right place in the lung to achieve maximum benefit 
while minimize systemic effects. Thus, selectively targeting EP receptor-mediated cell signalling 
pathways will likely yield positive implications for lung health and disease in the future. 
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